A General Approach Towards Triazole-Linked Adenosine Diphosphate Ribosylated Peptides and Proteins by Liu, Q. et al.
A General Approach Towards Triazole-linked Adenosine 
Diphosphate Ribosylated Peptides and Proteins 
Qiang Liu[a], Hans A. V. Kistemaker[a]#, Sagar Bhogaraju[b], Ivan Dikic[b], Herman S. Overkleeft[a], 
Gijsbert A. van der Marel[a], Huib Ovaa[c], Gerbrand J. van der Heden van Noort*[c] and Dmitri V. 
Filippov*[a] 
 
Abstract: Current chemistries to prepare Adenosine Diphosphate 
ribosylated (ADPr) peptides are not generally applicable due to the 
labile nature of this post-translational modification and its 
incompatibility with strong acidic conditions used in standard solid 
phase peptide synthesis protocols. We present a general strategy to 
prepare ADPr peptide analogues based on a copper catalysed click 
reaction between an azide modified peptide and an alkyne modified 
ADPr counterpart. We expand the scope of this approach to proteins 
by preparing two ubiquitin ADPr analogues carrying the biological 
relevant α-glycosidic linkage. Biochemical validation using 
Legionella effector enzyme SdeA shows that clicked ubiquitin ADPr 
is well tolerated and highlights the potential of this strategy to 
prepare ADPr proteins. 
Regulation of protein activity is controlled by post-translational 
modifications (PTMs) that are installed on specific side chain 
functionalities of amino acids in the involved protein. Simple 
PTMs such as acetylation, methylation and phosphorylation 
have been subject of a large amount of studies and the focus of 
PTM research is shifting to more complex PTMs. One of these 
PTMs is called adenosine diphosphate ribose (ADPr), a 
modification in which a specific nucleophilic side chain in the 
target protein displaces β-oriented nicotinamide from NAD+ 
under the agency of an ADPr-transferase (ART) resulting in an 
α-oriented linkage to the protein[1]. Mono-ADP-ribosylation is not 
only a PTM effected by bacterial toxins and the starting point for 
poly-ADP-ribosylation but also a regulatory modification in its 
own right. Mono-ADP-ribosylation is reported to take place on a 
variety of amino acid side chains including arginine (see Figure 
1), glutamic acid, aspartic acid, asparagine and cysteine but 
recently it was pointed out that serine might be the main point of 
attachment for ADP-ribosylation.[2] Research in the field of 
protein ADP-ribosylation benefits greatly from ADP-ribosylated 
molecular tools. One way to obtain such tools in sufficient 
quantities is through chemical synthesis. Methodologies towards 
naturally occurring mono-ADP-ribosylated oligopeptides, ADPr 
oligomers and NAD+-analogues have been reported and 
employed in studying ADP-ribosyl hydrolase affinity[3], inhibition 
of ADP-ribosylating toxins, finding substrate proteins for poly 
ADPr polymerases[4] and determining the structure of poly ADP-
ribose glycohydrolases.[5] Such ADPr peptides and related 
substances are valuable for the interrogation of the complex 
biology that underlies this PTM.[6] In the chemical synthesis of 
peptides and proteins most commonly an acidic step to remove 
protective groups is employed. Such conditions, however, may 
cause either epimerization at the anomeric center of ribose or 
complete loss of the ADPr-moiety. Mild alkaline conditions, carry 
the risk of degradation of the β-substituted amino acids and are 
clearly incompatible with the esters of ADP-ribosylated Glu and 
ADP-ribosylated Asp. The reported syntheses of ADPr amino 
acids and peptides so far have been carefully tuned to minimize 
those risks and incorporation of ADPr amino acids asks for a 
modified protective group strategy in most cases.[6a, 7] In order to 
prevent the need for highly specialized methods to prepare 
these amino acid-ribose conjugates we propose a general 
strategy that would allow a post-synthetic introduction of the 
ADPr moiety to a peptide or protein of interest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of α -linked ADPr arginine- and ADPr triazole analogue-
linkages. 
We selected the ADPr triazole analogues as a relevant 
replacement for ADPr amino acids in peptides (see Figure 1). 
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Oligopeptides with an azide incorporated can be obtained by 
standard solid phase peptide synthesis (SPPS) using an azido-
alanine or azido-homo alanine building block at the site of the 
modification. After conventional synthesis and a copper 
catalyzed azide alkyne cycloaddition (CuAAC) of the obtained 
azido functionalized oligopeptide with a suitable propargylated 
ADPr building block (ADPr-pr, 7 in Scheme 1) results in the 
installation of the ADPr triazole functionality.  
The synthesis of ADPr-pr 7 starts with the condensation of 
propargyl alcohol with imidate ribose donor 1[7a] (see Scheme 1) 
to yield an anomeric mixture (α:β, 71:29). In contrast to two 
previously reported syntheses that show the preparation of 
either β-O-alkyne or β-azide containing ADPr analogues we 
were able to isolate the biologically relevant α-anomer.[5, 8] 
Protective group exchange allows for an alkaline deprotection 
scheme in the final stage of the synthesis instead of acid 
treatment, preventing possible degradation of the ADPr-pr 
moiety. Phosphitylation of the primary alcohol and subsequent 
oxidation furnishes crucial phosphotriester intermediate 4. 
Removal of the tBu groups set the stage for the installation of 
the pyrophosphate moiety using our previously reported 
procedure.[9] Reaction of phosphomonoester 5 with suitably 
protected adenosine phosphoramidite 6[10] using 
dicyanoimidazole (DCI) as activator and oxidation of the 
intermediate P(III)-P(V) species was followed by a two-step 
alkaline deprotection procedure. Purification using size exclusion 
chromatography gave access to ADPr-pr 7 in a quantity of 100 
mg. Formation of the pyrophosphate and subsequent 
deprotection proceeded in an overall isolated yield of 65% which 
compares favorably to other approaches.[6a, 8, 11] 
 
 
 
 
 
 
 
Scheme 1. Synthesis of ADPr-propargyl 7 
To assess the viability of ADPr-pr building block 7 in the 
projected cycloaddition we prepared three peptides derived from 
mono-ADP-ribosylated proteins; namely Histone H2B (2-14) 
(see Scheme 2, compound 8), RhoA (36-46) (see Scheme 2, 
compound 9) and Human Neutrophil Defensin 1; HNP1 (75-81) 
(see Scheme 2, compound 10). In the selected peptides, we 
substituted Gln3, Asn50 and Arg78, respectively, for β-
azidoalanine to allow conjugation via copper catalyzed 
cycloaddition. After completion of the SPPS the immobilized 
oligopeptides were treated with a cleavage mixture consisting of 
90.5% trifluoroacetic acid (TFA), 5% water, 2.5% phenol and 2% 
triisopropylsilane to globally remove the protective groups and 
cleave the peptide from the resin. RP-HPLC purification yielded 
target peptides 8 – 10 that were used in the CuAAC reaction 
with ADPr-pr 7 in 20 mM  tris(hydroxymethyl)aminomethane / 
150 mM NaCl buffer at pH 7.6 under the agency of 10 mM 
CuSO4, 60 mM sodium ascorbate and 10 mM tris triazole 
ligand.[12] Since these peptides and ADPr-pr 7 dissolved readily 
in this buffer, the click reaction proceeded efficiently and quickly 
(within minutes to one hour) in contrast to a previous study.[8] In 
order to mimic the length of the Arg-ADPr linkage more closely 
we prepared HNP1-peptide 11 in which the Arg was replaced 
not with β-azidoalanine but with azido-homoalanine. Again 
CuAAC to ADPr-pr proceeded uneventfully, yielding 15. 
 
 
 
 
Scheme 2. CuAAC reaction towards ADPr peptides 
Having established an efficient protocol to prepare ADPr 
oligopeptides we were eager to see whether our methodology 
could be expanded in preparation of ADPr proteins. Ubiquitin 
(Ub), a 76 amino acid residue long post-translational modifier 
itself, has recently been found to be modified with ADPr on 
different positions. This cross-talk between ADP-ribosylation and 
ubiquitination is reported to have a regulatory effect on the DNA 
repair mechanism, where low levels of NAD lead to 
ubiquitination of histone protein H4, but high levels of NAD lead 
to ADP-ribosylation of Gly76; the C-terminus of Ub.[13] Other 
studies show that Arg42 of Ub is ADP-ribosylated by a family of 
effector proteins originating from Legionella pneumophila, the 
pathogen causing Legionnaires disease.[14] These SidE effectors 
are the first reported class of enzymes that are able to 
ubiquitinate target proteins independent of the normally 
employed enzymatic cascade of E1, E2 and E3 enzymes, 
utilizing Ub-ADPr as crucial intermediate. Using their unique 
properties, SidE proteins can hijack the host cells Ub pool and 
use it to its own advantage. In analogy to peptide 11, we 
prepared Ub mutant 16 in which Arg42 is replaced by azido-
homoalanine using our previously published linear SPPS 
approach.[15] Gly76 modified Ub 17 was prepared by first 
synthesizing Ub75 on trityl resin followed by treatment with mild 
acid (20% hexafluoroisopropanol in dichloromethane). In this 
step the peptide was liberated from the solid support while 
leaving all side-chain protecting groups in place. Activation of 
the free C-terminal carboxylic acid and coupling of 3-azido-1-
propanamine followed by strong acid treatment and RP-HPLC 
purification yielded azide modified Ub 17. Copper catalyzed click 
reaction with ADPr-pr building block 7 followed by dialysis to 
remove traces of excess ADPr-pr and click reagents followed by 
size exclusion chromatography gave easy access to ADP-
ribosylated ubiquitin analogues 18 and 19, respectively (see 
Scheme 3). 
 
 
 
 
Scheme 3. CuAAC reaction towards Ub-ADPr conjugates. 
Of note is that this workflow does not require the use of RP-
HPLC purification after introduction of the ADPr moiety. In order 
to assess whether the artificial triazole linkage is tolerated and 
this methodology indeed results in useful ADPr-protein 
analogues, we compared Ub-ADPr 18 to Arg42 Ub-ADPr from 
natural sources (Ub-ADPr wt). Both Ub-ADPr 18 and Ub-ADPr 
wt were efficiently recognized by an ADPr-antibody in Western 
Blot (see Figure 2A, lower panel), a first indication that the 
triazole analogue does not differ too far from its natural 
counterpart. One of the properties of Legionella effector SdeA is 
its auto-ubiquitination behaviour, an effect that is not fully 
understood so far, but is reported for all four SidE family 
members. We compared the ability of recombinant SdeA to use 
18 in an auto-ubiquitination assay and found indeed that SdeA is 
modified with Ub multiple times (see Figure 2A, B). Although at 
a reduced rate compared to Ub-ADPr wt, artificial 18 was 
processed by SdeA and significant auto-ubiquitination takes 
place. A control experiment using non-ADPribosylated wild type 
Ub shows no auto-ubiquitination of SdeA (see Supporting 
Information Figure 1).  These results further confirm that Ub-
ADPr conjugate 18 functions similar to Ub-ADPr wt.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of Arg42 Ub-ADPr wt and Ub-ADPr analogue 18 
processing by SdeA at A) 30 min and B) 90 min. 
In conclusion, we here present the design and synthesis of 
propargylated ADP-ribose building block (7) suitable to take part 
in an efficient cycloaddition with oligopeptides and proteins 
having an azide at a predetermined position. In this way 
oligopeptides and proteins carrying an analogue of the mono 
ADP-ribose post-translational modification are made available. 
Four ADPr-oligopeptide conjugates derived from known ADP-
ribosylated proteins were prepared efficiently. In addition, two 
analogues of ADPr ubiquitin, shown to play a role in 
Legionnaires disease and DNA repair, were prepared using the 
same copper catalyzed chemistry. The effectiveness of these 
reactions and subsequent purifications provides an easy entry to 
this interesting class of post-translational modified proteins. 
Triazole containing Ub-ADPr 18 was shown to be recognized in 
Western Blot and accepted by SdeA in an auto-ubiquitination 
assay, indicating that this methodology provides a useful 
platform for the biological interrogation of ADPr biology. 
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COMMUNICATION 
ADPr-Ub-date. A general strategy to prepare ADPr peptide and protein analogues 
based on a copper catalysed click reaction between an azide modified peptide or 
protein and an alkyne modified ADPr counterpart is presented. The first fully 
synthetic ADPribosylated protein analogues carrying the biological relevant α-
glycosidic linkage were prepared and biochemical validation shows that clicked 
ADPr Ubiquitin is tolerated, highlighting the potential of this strategy. 
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